
Anaheim Bio launches with €40 million Series A financing
Alesta Therapeutics spin-out Anaheim Bio has launched with an oversubscribed €40 million Series A financing. The company was formed in 2026 from programmes spun out of Alesta Therapeutics and is backed by Alesta's former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja… Read More









